Emerging pharmaceutical markets are no longer only peripheral demand pools for products developed, manufactured and priced elsewhere. They are increasingly becoming strategic regions where demographic pressure, expanding access to care, industrial policy, local manufacturing and geopolitical risk converge. This working paper examines the changing role of pharmerging markets across Asia, Africa, Latin America, the Gulf region, Central-Eastern Europe and Turkey. It argues that the relevant question is no longer only how fast these markets will grow, but what functions they will perform within the global pharmaceutical value chain: end markets, manufacturing platforms, regional hubs, fill-finish locations, technology-transfer environments or combinations of these roles. For European and Italian life science companies, the opportunity is significant but selective. The most defensible strategies are likely to be based on partnership, regulatory competence, quality manufacturing, local presence, technology transfer and a careful reading of access systems, rather than on export alone.